Revised SPC: Neulasta (pegfilgrastim) products
SPC now includes data from post-marketing observational study of pegfilgrastim in conjunction with chemotherapy and/or radiotherapy showing link to development of myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients.
Source:
electronic Medicines compendium